Platinum-Resistant Ovarian Cancer

  • STATUS
    Recruiting
Updated on 18 February 2020
platinum-resistant ovarian cancer

Summary

A Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen (innovaTV 208)

Women with platinum resistant ovarian cancer are asked to participate in a research study being conducted by Icahn School of Medicine at Mount Sinai.

 

Details
Condition Ovarian Cancer
Clinical Study IdentifierTX217927
Last Modified on18 February 2020

Eligibility

Yes No Not Sure

Inclusion Criteria

Is your age greater than or equal to 18 yrs?
Are you female?
Do you have Ovarian Cancer?
You may be eligible to participate in this study if you
Are a female at least 18 years of age or older
Have histologic documentation of epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer
You may not participate in this study if you
Have primary platinum-refractory disease, defined as disease progression within 2 months of completion of first line platinum-based therapy
Have had gastrointestinal obstruction within the past 6 months or who currently require parenteral nutrition
Have known past or current coagulation defects leading to an increased risk of bleeding
Have clinically significant cardiac disease
Have active ocular surface disease
Have ongoing, acute, or chronic inflammatory skin disease
Have uncontrolled tumor-related pain
Have Inflammatory lung disease requiring chronic medical therapy
Have Grade 3 or higher pulmonary disease unrelated to underlying malignancy
Have Grade >1 peripheral neuropathy
Have inflammatory bowel disease including Crohn’s disease and ulcerative colitis
Are pregnant, breastfeeding or plan to become pregnant
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note